STOCK TITAN
  1. Home
  2. News
  3. CPRX

Catalyst Pharmaceuticals Inc - CPRX STOCK NEWS

Welcome to our dedicated news page for Catalyst Pharmaceuticals (Ticker: CPRX), a resource for investors and traders seeking the latest updates and insights on Catalyst Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Catalyst Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Catalyst Pharmaceuticals's position in the market.

News
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share, totaling gross proceeds of $150,000,000 before deducting underwriting discounts and expenses. Catalyst also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock offered in the public offering. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.85%
Tags
offering
-
News
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) has announced the commencement of an underwritten public offering of $150,000,000 of its common stock. The company also plans to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock. The offering is subject to market conditions, and the net proceeds will be used to fund the potential acquisition of new product candidates and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.85%
Tags
offering
-
News
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced that its collaboration partner, DyDo Pharma, Inc., has submitted a New Drug Application to Japan's Pharmaceuticals and Medical Devices Agency seeking marketing approval for FIRDAPSE for the treatment of Lambert Eaton myasthenic syndrome in Japan. The review period is expected to be approximately a minimum of nine months from the submission date. This submission represents a pivotal milestone in the mission to broaden FIRDAPSE’s access as a treatment for LEMS patients in Japan, potentially offering a novel treatment option for Japanese individuals grappling with this condition. Catalyst is also eligible to receive a milestone payment from DyDo and extend its territorial rights to develop and market the product in other key markets in Asia, Central, and South America.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
none
News
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) has been ranked 4th on Forbes' list of America's Most Successful Small-Cap Companies for 2024. The ranking is based on positive sales growth over the last twelve months and includes criteria such as earnings growth, sales growth, return on equity, and total stock return. Catalyst's Chairman and CEO, Patrick J. McEnany, expressed gratitude for the recognition and attributed the company's success to the dedication of its employees and commitment to rare disease patient communities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.38%
Tags
none
-
News
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) appoints Michael W. Kalb as Executive Vice President and Chief Financial Officer, announces retirement of CFO Alicia Grande and promotions of Dr. Steven Miller and Jeffrey Del Carmen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
management
-
News
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. (CPRX) announces participation in the Piper Sandler 35th Annual Healthcare Conference. The company's Chairman and CEO, Patrick J. McEnany, and other members of the management team will host 1x1 meetings and a fireside discussion at the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
conferences
News
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. (CPRX) reported a 79.4% increase in YOY net revenues to $102.7 million in Q3 2023. GAAP net loss per share was $(0.29) due to an $81.5 million one-time IPR&D expense. Non-GAAP net income was $55.9 million. Recent highlights include FDA approval of AGAMREE for Duchenne Muscular Dystrophy and a sNDA for FIRDAPSE. The company raised its 2023 revenue guidance to $390-395 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
earnings
-
News
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
Rhea-AI Summary
Catalyst Pharmaceuticals has received notification from the USPTO that two additional patents covering FIRDAPSE will be granted in the next two months. These patents are for claims associated with the bioavailability of FIRDAPSE under fasting and fed conditions of dosing. FIRDAPSE is the only approved treatment for Lambert-Eaton myasthenic syndrome in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
none
-
News
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. will participate in the 11th Annual Epilepsy Awareness Day & Education Expo to raise awareness and education with the epilepsy community. The event is jointly organized by Sofie's Journey and Epilepsy Alliance of America and aims to help patients living with epilepsy. Catalyst's partnership underscores a shared commitment to raising awareness and making a positive impact on those affected and their families. Over 3.4 million people in the U.S. are affected by epilepsy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
partnership
News
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
Rhea-AI Summary
Santhera Pharmaceuticals has obtained FDA approval for AGAMREE® (vamorolone) for the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged two years and older. Catalyst Pharmaceuticals holds the exclusive North American license for AGAMREE and plans to commercially launch the drug in Q1 2024. AGAMREE offers a novel corticosteroid treatment option for DMD, with a favorable side effect profile compared to current standard-of-care corticosteroids. Catalyst expects AGAMREE to have a positive impact on the treatment paradigm for DMD and potentially other chronic inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.78%
Tags
fda approval
Stock CPRX logo
Catalyst Pharmaceuticals Inc

Nasdaq:CPRX

CPRX Rankings

#1949 Ranked by Market Cap
#2926 Ranked by Stock Gains
N/A Ranked by Dividends

CPRX Stock Data

1.80B
101.40M
6.21%
73.15%
5.14%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Coral Gables

About CPRX

catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso